Preclinical Pharmacology for Oncology Programs
Led by Dr. Hui Qin Wang, a preclinical pharmacologist with 20+ years in oncology drug development. We integrate PK/PD, efficacy, and biomarker strategy to bring clarity to go/no-go decisions from discovery through early clinical.
Expertise in oncology pharmacology: PK/PD, biomarker strategy, efficacy modeling, and translational insight for small molecules, biologics, ADCs, and immune cell engagers.
Core Focus Areas
Exposure–response thinking for first-in-human and early clinical: PK/PD integration, dose range scenarios, and transparent assumptions that stand up to review.
Define decision-enabling biomarkers, link preclinical efficacy to clinical endpoints, and align cross-functional teams on translational read-outs.
Small molecules, biologics, ADCs, and immune cell engagers—clear pharmacology narratives tailored to the modality and mechanism of action.